Biotechnology platform Mykor has successfully closed a £4 million funding round, elevating its total capital raised to £7.5 million. The latest investment, led by Clean Growth Fund and The FSE Group, accelerates the commercialization of low-carbon building materials intended to decarbonize the built environment. Concurrently, the firm announced securing over £338 million in commercial agreements across the United Kingdom and Europe.
For infrastructure leaders and facility executives, achieving rigorous sustainability targets while maintaining operational integrity is an ongoing requirement. Mykor seeks to resolve this by converting agricultural and industrial waste streams into scalable materials. Crucially for institutional infrastructure and complex facility developments, these biomaterials are engineered to meet strict benchmarks for fire safety, durability, and affordability necessary for large-scale adoption.
The company’s biotechnology platform integrates proprietary engineered mycelium strains, green chemistry additives, and a closed-loop biofabrication process. This approach yields a new generation of products designed to either supplement or entirely replace conventional, carbon-heavy options. Initial applications include:
- Advanced prefabricated wall systems
- Cavity wall insulation products
By leveraging agricultural byproducts as primary feedstocks, the production method intrinsically minimizes waste while supplying commercially viable solutions to developers and contractors aiming to lower the embodied carbon of their projects.
Rather than operating exclusively as a standalone product manufacturer, Mykor functions as a scalable technology provider. This platform-based strategy enables manufacturing partners and contractors to integrate these low-carbon building materials directly into existing supply chains and production facilities. For executives overseeing complex developments within the built environment, this approach facilitates the adoption of sustainable construction methods without enduring significant operational disruptions.
Driven by increasing public and private sector demand, the newly acquired capital will be directed toward expanding production capabilities and advancing further product development. Additionally, the funds will strengthen strategic industry partnerships, facilitating Mykor’s targeted expansion into key European markets to fulfill its extensive pipeline of commercial agreements.
